FDA cites litany of er­rors at Lon­za Hous­ton plant at the cen­ter of Bris­tol My­ers CVR de­ba­cle

In­vestors’ some­what long­shot bet on a $9 CVR tied to Bris­tol My­ers Squibb’s ac­qui­si­tion of Cel­gene came to a screech­ing halt last month af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.